Related content

Evaluation of EGFR, KRAS, and TP53 mutations as predictive of disease recurrence in resected early non-small cell lung carcinomas (NSCLCs)

By Bar Jair   Damianovich Maya   Siloni Goni Hout   Dar Erel   Cohen Yehudit   Zadok Oranit   Cohen Yoram   Perelman Marina   Barshack Iris   Yarden Ronit I   Simansky David   Ben Nun Alon   Onn Amir  

memo - Magazine of European Medical Oncology, Vol. 7, Iss. 1, 2014-02 ,pp. : 10-15

Springer Publishing Company

Access to resources Recommend Favorite

Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer

By Lim Ken-Hong   Huang Ming-Jer   Liu Hung-Chang   Kuo Hsu-Tah   Tzen Chin-Yuan   Hsieh Ruey-Kuen  

Medical Oncology, Vol. 24, Iss. 4, 2007-12 ,pp. : 388-393

Humana Press, Inc

Access to resources Recommend Favorite

EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases

By Luo Dongdong   Ye Xin   Hu Zheng   Peng Kaiwen   Song Ye   Yin Xiaolu   Zhu Guanshan   Ji Qunsheng   Peng Yuping  

Tumor Biology, Vol. 35, Iss. 3, 2014-03 ,pp. : 2437-2444

Springer Publishing Company

Access to resources Recommend Favorite

Impact of EGFR mutations on treatment of non-small cell lung cancer

By Johnson Bruce   Jackman David   Jänne Pasi  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 7, 2006-11 ,pp. : 5-9

Springer Publishing Company

Access to resources Recommend Favorite

Impact of EGFR mutations on treatment of non-small cell lung cancer

By Johnson Bruce   Jackman David   Jänne Pasi  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 1, 2006-11 ,pp. : 5-9

Springer Publishing Company

Access to resources Recommend Favorite